Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p74 | Bone development/growth and fracture repair | ECTS2016

In vitro investigation of the effect of Magnetic Resonance guided Focused Ultrasound Surgery on osteosarcoma cell lines

Agnese Valentina , Costa Viviana , Carina Valeria , Bellavia Daniele , Raimondi Lavinia , De Luca Angela , Scoarughi Gianluca , Midiri Massimo , Stassi Giorgio , Giavaresi Gianluca

Aim: Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS) is an invasive treatment able to control local disease and pain of bone tumors. Unfortunately, there is not any scientific evidence of the biological effect of MRgFUS treatment on tumor cells, especially in lower dose region, where tissues are only warmed to sub-lethal temperatures. Here we investigate the effect of in vitro MRgFUS treatment, at different levels of acoustic energy (200–630 J), on ...

ba0005p108 | Cancer and bone: basic, translational and clinical | ECTS2016

Clinical and experimental evidence suggest a protective effect of Paget’s disease of bone against skeletal metastasization from solid tumors

Merlotti Daniela , Rucci Nadia , Rendina Domenico , Bianciardi Simone , Evangelista Isabella Anna , Ucci Argia , Rotatori Stefano , Sebastiani Guido , Dotta Francesco , Cenci Simone , Strazzullo Pasquale , Nuti Ranuccio , Teti Anna , Gennari Luigi

Paget’s disease of bone (PDB) is a common disorder of bone metabolism characterized by focal areas of excessive and rapid bone resorption and formation, leading to bone pain, deformity and fractures. Despite the well documented increase in the risk of primary bone tumors due to neoplastic degeneration of pagetic tissue, a large retrospective analysis suggested that patients with prostate cancer and PDB have delayed time to bone metastases and improved overall survival tha...

ba0005p113 | Cancer and bone: basic, translational and clinical | ECTS2016

Dendritic glycopolymers as efficient drug delivery systems for retarded release of bortezomib from calcium phosphate cements

Mamitzsch Bettina , Striegler Christin , Schumacher Matthias , Gelinsky Michael , Muller Martin , Seckinger Anja , Voit Brigitte , Appelhans Dietmar

Calcium phosphate cements (CPC) are used as bone graft substitute, e.g. in the treatment of lytic bone lesions in multiple myeloma. CPC provide crucial advantages, such as osteoconductivity, biodegradability and the potential drug loading. Though, it lacks retarded drug release for short-/long-term treatment due to the free diffusion of small molecules through the micropores in the CPC.Thus we present dendritic glycopolymers (DG) consisting of poly(ethyl...

ba0005p121 | Cancer and bone: basic, translational and clinical | ECTS2016

MCT1 as a novel target for the treatment of osteolytic bone metastases

Avnet Sofia , Lemma Silvia , Di Pompo Gemma , Sboarina Martina , Porporato Paolo , Perez-Escuredo Jhudit , Sonveaux Pierre , Baldini Nicola

Bone metastasis (BM) is a dismal complication of cancer, occurring frequently in patients with advanced breast carcinoma. During metastatic progression, carcinoma cells harness osteoclast (OC) activity, promoting osteolysis. To adapt to hypoxia and/or to support proliferation, carcinoma cells adopt primarily glycolysis for energy production, therefore releasing lactic acid in the microenvironment through monocarboxylate transporter 4 (MCT4). Stressed by tumor cells, osteoblast...

ba0005p123 | Cancer and bone: basic, translational and clinical | ECTS2016

The SRC kinase inhibitor saracatinib limits the development of osteolytic bone disease in multiple myeloma

Heusschen Roy , Muller Josephine , Binsfeld Marilene , Plougonven Erwan , Mahli Nadia , Carmeliet Geert , Leonard Angelique , Cohen-Solal Martine , Vanderkerken Karin , Beguin Yves , Menu Eline , Caers Jo

Destructive bone lesions due to osteolytic bone disease (OBD) are a major cause of morbidity and mortality in multiple myeloma (MM) patients and the development of new therapeutic strategies is of great interest. In this study, we assessed the effect of SRC inhibition with saracatinib (AZD0530, AstraZeneca) on the development of MM and its associated OBD. We first determined SRC family kinase expression in the MM microenvironment and found that myeloma cells express SRC at low...

ba0005p199 | Cell biology: osteoclasts and bone resorption | ECTS2016

Identification of G protein-coupled receptor 137B (GPR137b) function in mouse and zebrafish osteoclasts

Urso Katia , Caetano-Lopes Joana , Lee Pui , Henke Katrin , Sury Meera , Duryea Jeff , Nigrovic Peter , Aliprantis Antonios , Harris Matt , Charles Julia

Analysis of genome wide data such as transcriptomics can identify genes of potential interest to bone biology. These techniques are primarily hypothesis-generating. Determining the role of candidate factors in bone ultimately requires in vivo experiments. Gene expression analysis of mouse osteoclast differentiation identified G protein-coupled receptor 137B (GPR137b) as highly upregulated. GPR137b is an orphan seven-pass transmembrane receptor of unknown func...

ba0005p242 | Genetics and Epigenetics | ECTS2016

A family with Paget disease of bone caused by a novel mutation of hnRNPA2B1 gene

Qi Xuan , Pang Qianqian , Wang Jiawei , Zhao Zhen , Wang Ou , Xu Lijun , Mao Jiangfeng , Jiang Yan , Li Mei , Xing Xiaoping , Yu Wei , San A , Xia Weibo

Paget disease of bone (PDB) is a common metabolic bone disease characterized by increased bone resorption and disorganized bone formation which can affect single or multiple sites of bone. Although the exact cause of PDB is still controversial, genetic factor is considered to play an important role in PDB. The causative gene of classical PDB was identified as Q8STM1 gene. Familial expansile osteolysis caused by the mutation of TNFRSF11A(RANKL) gene a...

ba0005p249 | Genetics and Epigenetics | ECTS2016

Identification of epigenomic regulators of osteoblast function

Henaff Carole Le , Partridge Nicola , Jehan Frederic , Geoffroy Valerie

Molecularly characterized epigenetic networks that control bone formation and are altered during aging are necessary to uncover new potential targets for osteoanabolic therapy. Our contribution to the iBONE consortium is to identify osteoanabolic epigenomic regulators by screening which are involved in osteoblast phenotype and differentiation. This study will be done by a 3 step approach including: siRNA screening for epigenomic regulators of osteoblastic differentiation and v...

ba0005p300 | Osteoporosis: evaluation and imaging | ECTS2016

Bio-impedance and quantitative ultrasound to measure bone mineral density in post-menopausal women from a rural Mexican community

Blanco-Rodriguez Fernando , Ellis-Infante Nicole , Lopez-Rivas Victor , May-Kim Sherlin , Pickett Charlotte , Pacheco-Pantoja Elda

It is widely accepted that the “gold” standard method for diagnosis of osteoporosis is dual energy X-ray absorptiometry, to measure bone mineral content and bone mineral density (BMD). However in the last decades other less harmful and cheaper methods were developed. Among them bioelectrical impedance analysis (BIA) is one of most commonly used and is used in analysis of body composition as well. On its side, quantitative ultrasound (QUS) is a noninvasive method of e...

ba0005p306 | Osteoporosis: evaluation and imaging | ECTS2016

To measure or not to measure? Vitamin D and parathyroid hormone in patients with clinical risk factors for osteoporosis

Bock Oliver , Pyttel Susanne , Dostmann Ute

Background: Despite the large amount of studies published on the association of vitamin D deficiency with higher incidence of falls and fractures, the threshold for a sufficient serum 25(OH)D concentration remains subject to a considerable debate. There has also been no clear consensus on the assessment and treatment of vitamin D deficiency.Objective: To examine the prevalence of vitamin D deficiency and/or insufficiency and its impact on calcium/phospha...